NYSE:ELAN - Elanco Animal Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.39
  • Forecasted Upside: -12.72 %
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$31.38
▲ +0.2 (0.64%)
1 month | 3 months | 12 months
Get New Elanco Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELAN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$27.39
▼ -12.72% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Elanco Animal Health in the last 3 months. The average price target is $27.39, with a high forecast of $32.00 and a low forecast of $19.00. The average price target represents a -12.72% upside from the last price of $31.38.
Buy
The current consensus among 11 contributing investment analysts is to buy stock in Elanco Animal Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/7/2020Raymond JamesReiterated RatingHoldMedium
i
10/1/2020CitigroupBoost Price TargetBuy$27.00 ➝ $32.00Medium
i
9/28/2020Raymond JamesReiterated RatingHoldLow
i
8/20/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$24.00 ➝ $31.00High
i
8/18/2020ArgusBoost Price TargetPositive ➝ Buy$26.00 ➝ $30.00Low
i
8/12/2020Credit Suisse GroupInitiated CoverageNeutral$27.00Medium
i
8/4/2020Goldman Sachs GroupInitiated CoverageBuy$26.50High
i
7/27/2020Cleveland ResearchDowngradeNeutral ➝ Underperform$19.00High
i
7/20/2020Bank of AmericaBoost Price TargetBuy$26.00 ➝ $28.00Low
i
5/15/2020CitigroupLower Price TargetBuy$35.00 ➝ $27.00Medium
i
5/13/2020BarclaysReiterated RatingBuy$25.00Medium
i
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
i
3/25/2020Credit Suisse GroupReiterated RatingBuyHigh
i
1/14/2020GabelliReiterated RatingBuyHigh
i
Rating by Kevin Kedra at Gabelli
1/9/2020Raymond JamesInitiated CoverageMarket PerformHigh
i
12/19/2019Bank of AmericaUpgradeNeutral ➝ Buy$34.00High
i
11/20/2019UBS GroupLower Price TargetNeutral$30.00 ➝ $28.00Low
i
11/7/2019Morgan StanleyUpgradeEqual ➝ Equal Weight$34.00 ➝ $32.00Medium
i
9/26/2019Cleveland ResearchReiterated RatingHoldLow
i
Rating by Rob Eich at Cleveland Research
9/23/2019BarclaysInitiated CoverageOverweight$36.00Medium
i
9/9/2019Goldman Sachs GroupInitiated CoveragePositiveMedium
i
8/26/2019Bank of AmericaDowngradeBuy ➝ Neutral$30.00Low
i
Rating by Michael Ryskin at Bank of America Co.
8/15/2019UBS GroupUpgradeSell ➝ Neutral$31.00 ➝ $30.00Medium
i
5/22/2019GuggenheimInitiated CoverageNeutral ➝ NeutralLow
i
5/10/2019BMO Capital MarketsBoost Price TargetMarket Perform$32.00 ➝ $35.00Low
i
3/20/2019UBS GroupInitiated CoverageSell$29.00 ➝ $28.00Low
i
3/18/2019Bank of AmericaUpgradeNeutral ➝ Buy$30.95Low
i
3/13/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$34.00Low
i
Rating by David Risinger at Morgan Stanley
2/11/2019William BlairInitiated CoverageMkt Perform ➝ Market Perform$29.71Medium
i
Rating by J. Kreger at William Blair
1/23/2019UBS GroupInitiated CoverageSell ➝ Sell$29.00High
i
1/15/2019ArgusInitiated CoverageBuy$37.00Low
i
1/4/2019Credit Suisse GroupReiterated RatingHold$33.00Low
i
12/19/2018BMO Capital MarketsLower Price TargetMarket Perform$37.00 ➝ $32.00High
i
12/17/2018Credit Suisse GroupReiterated RatingHold$36.00High
i
11/13/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$33.00 ➝ $37.00Low
i
10/15/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$36.00High
i
10/15/2018CitigroupInitiated CoverageBuy ➝ Buy$37.00High
i
10/15/2018CowenInitiated CoverageOutperformLow
i
10/15/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$34.00Low
i
10/15/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$35.00Low
i
10/15/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$38.00Low
i
10/15/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$30.00Low
i
10/12/2018Craig HallumInitiated CoverageHoldLow
i
9/26/2018BMO Capital MarketsInitiated CoverageMarket Perform$33.00High
i
9/19/2018GabelliInitiated CoverageBuy ➝ Buy$32.00N/A
i
Rating by K. Kedra at Gabelli
(Data available from 10/25/2015 forward)
Elanco Animal Health logo
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
Read More

Today's Range

Now: $31.38
$30.90
$31.43

50 Day Range

MA: $28.84
$26.27
$33.79

52 Week Range

Now: $31.38
$15.17
$34.09

Volume

1,273,959 shs

Average Volume

5,126,406 shs

Market Capitalization

$12.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04